JP2008535835A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535835A5
JP2008535835A5 JP2008505262A JP2008505262A JP2008535835A5 JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5 JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008505262 A JP2008505262 A JP 2008505262A JP 2008535835 A5 JP2008535835 A5 JP 2008535835A5
Authority
JP
Japan
Prior art keywords
amino
formula
compound
thiazolo
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008505262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535835A (ja
JP5165553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/000399 external-priority patent/WO2006107258A1/en
Publication of JP2008535835A publication Critical patent/JP2008535835A/ja
Publication of JP2008535835A5 publication Critical patent/JP2008535835A5/ja
Application granted granted Critical
Publication of JP5165553B2 publication Critical patent/JP5165553B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

JP2008505262A 2005-04-06 2006-04-03 新規な５−置換された７−アミノ［１，３］チアゾロ［４，５−ｄ］ピリミジン誘導体 Active JP5165553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0500767-9 2005-04-06
SE0500767 2005-04-06
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2008535835A JP2008535835A (ja) 2008-09-04
JP2008535835A5 true JP2008535835A5 (enExample) 2009-06-04
JP5165553B2 JP5165553B2 (ja) 2013-03-21

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505262A Active JP5165553B2 (ja) 2005-04-06 2006-04-03 新規な５−置換された７−アミノ［１，３］チアゾロ［４，５−ｄ］ピリミジン誘導体

Country Status (30)

Country Link
US (2) US7947693B2 (enExample)
EP (1) EP1869056B1 (enExample)
JP (1) JP5165553B2 (enExample)
KR (1) KR101335055B1 (enExample)
CN (1) CN101193897B (enExample)
AR (1) AR055890A1 (enExample)
AT (1) ATE487727T1 (enExample)
AU (1) AU2006231836B2 (enExample)
BR (1) BRPI0609738A2 (enExample)
CA (1) CA2604017C (enExample)
CY (1) CY1111316T1 (enExample)
DE (1) DE602006018124D1 (enExample)
DK (1) DK1869056T3 (enExample)
ES (1) ES2354450T3 (enExample)
HR (1) HRP20110047T1 (enExample)
IL (1) IL185912A0 (enExample)
MX (1) MX2007012060A (enExample)
NO (1) NO20075603L (enExample)
NZ (1) NZ561460A (enExample)
PL (1) PL1869056T3 (enExample)
PT (1) PT1869056E (enExample)
RS (1) RS51581B (enExample)
RU (1) RU2419623C2 (enExample)
SA (1) SA06270072B1 (enExample)
SI (1) SI1869056T1 (enExample)
TW (1) TW200714605A (enExample)
UA (1) UA90707C2 (enExample)
UY (1) UY29454A1 (enExample)
WO (1) WO2006107258A1 (enExample)
ZA (1) ZA200708187B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
CN101522693B (zh) 2006-09-29 2012-01-04 阿斯利康(瑞典)有限公司 5，7-二取代的[1，3]噻唑并[4，5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
PL2254870T3 (pl) 2008-03-07 2016-07-29 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
EP2262778B8 (en) 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
US8314099B2 (en) 2008-03-07 2012-11-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1 and CX3CR1
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
JO3082B1 (ar) 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
CN105073727B (zh) 2013-03-12 2017-02-22 卫材R&D管理有限公司 吡咯烷‑3‑基乙酸衍生物的盐及其晶体
KR20160092991A (ko) * 2013-09-27 2016-08-05 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
US20180222922A1 (en) * 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
AU2023362450A1 (en) 2022-10-19 2025-05-29 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3 cr1
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (enExample) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
SI0891978T1 (en) * 1997-07-18 2002-06-30 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
AU3213699A (en) 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists
ATE361931T1 (de) 1998-05-01 2007-06-15 Lilly Co Eli N1 modifizierte glycopeptide
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1257555B1 (en) * 2000-02-11 2003-12-03 AstraZeneca AB Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP3597262B1 (en) * 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
JP2008524186A (ja) * 2004-12-17 2008-07-10 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Similar Documents

Publication Publication Date Title
JP2008535835A5 (enExample)
CA2604017A1 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
JP2008535834A5 (enExample)
US9133128B2 (en) Pyrazole derivatives as cannabinoid receptor 1 antagonists
TWI404721B (zh) 胺基－雜環化合物
JP2017518981A5 (enExample)
JP2004528312A5 (enExample)
CN102387704A (zh) S1p5受体的激动剂和拮抗剂，和其用法
RU2007140552A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 5, 7-ДИЗАМЕЩЕННОГО [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3H)-ОНА
JP2005516067A5 (enExample)
KR20160038008A (ko) 브로모도메인 억제제로서 신규 퀴나졸리논
JP2005525323A5 (enExample)
JP2005536475A5 (enExample)
EA010596B1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
JP2006522747A5 (enExample)
JP2006522749A5 (enExample)
RU2005128775A (ru) Производные пиперидинбензолсульфамида
JP2006523216A5 (enExample)
IL273169B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP2010504344A5 (enExample)
JP2011500621A5 (enExample)
JP2005525322A5 (enExample)
JP2008539268A5 (enExample)
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
IL297734A (en) Imidazopyrimidines as il-17 modulators